KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Total Liabilities (2016 - 2025)

Emergent BioSolutions' Total Liabilities history spans 16 years, with the latest figure at $796.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 12.23% year-over-year to $796.0 million; the TTM value through Dec 2025 reached $796.0 million, down 12.23%, while the annual FY2025 figure was $796.0 million, 12.23% down from the prior year.
  • Total Liabilities reached $796.0 million in Q4 2025 per EBS's latest filing, down from $878.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.8 billion in Q4 2022 to a low of $796.0 million in Q4 2025.
  • Average Total Liabilities over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • Peak YoY movement for Total Liabilities: soared 44.98% in 2023, then crashed 34.77% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $1.3 billion in 2021, then surged by 32.12% to $1.8 billion in 2022, then plummeted by 34.0% to $1.2 billion in 2023, then decreased by 22.74% to $906.9 million in 2024, then dropped by 12.23% to $796.0 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Total Liabilities are $796.0 million (Q4 2025), $878.5 million (Q3 2025), and $880.9 million (Q2 2025).